Hany W Darwish

List of Publications by Year
in descending order

73	1,202	279701	434063
papers	citations	23 h-index	31 g-index

76	76	76	883
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Synthesis, spectroscopic and computational studies on hydrogen bonded charge transfer complex of duvelisib with chloranilic acid: Application to development of novel 96-microwell spectrophotometric assay. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2022, 264, 120287.	2.0	10
2	Synthesis, spectroscopic and computational characterization of charge transfer complex of remdesivir with chloranilic acid: Application to development of novel 96-microwell spectrophotometric assay. Journal of Molecular Structure, 2022, 1263, 133104.	1.8	3
3	Irbesartan (a comprehensive profile). Profiles of Drug Substances, Excipients and Related Methodology, 2021, 46, 185-272.	3.5	6
4	Novel spectrofluorimetric determination of brigatinib in bulk powder and human urine samples via ion-pair complex formation using eosin Y. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2021, 249, 119210.	2.0	2
5	Experimental and Computational Evaluation of Chloranilic Acid as an Universal Chromogenic Reagent for the Development of a Novel 96-Microwell Spectrophotometric Assay for Tyrosine Kinase Inhibitors. Molecules, 2021, 26, 744.	1.7	7
6	Full spectrum and genetic algorithm-selected spectrum-based chemometric methods for simultaneous determination of azilsartan medoxomil, chlorthalidone, and azilsartan: Development, validation, and application on commercial dosage form. Open Chemistry, 2021, 19, 205-213.	1.0	1
7	Development and validation of a stability indicating RP-HPLC-DAD method for the determination of bromazepam. PLoS ONE, 2021, 16, e0244951.	1.1	7
8	Spectrophotometric and computational investigations of charge transfer complexes of chloranilic acid with tyrosine kinase inhibitors and application to development of novel universal 96-microwell assay for their determination in pharmaceutical formulations. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2021, 252, 119482.	2.0	10
9	A Validated LCâ€“MS/MS Assay for the Simultaneous Quantification of the FDA-Approved Anticancer Mixture (Encorafenib and Binimetinib): Metabolic Stability Estimation. Molecules, 2021, 26, 2717.	1.7	7
10	Solid-state potentiometric sensor for the rapid assay of the biologically active biogenic amine (tyramine) as a marker of food spoilage. Food Chemistry, 2021, 346, 128911.	4.2	27
11	Response surface methodology for optimization of micellar-enhanced spectrofluorimetric method for assay of foretinib in bulk powder and human urine. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2021, 257, 119811.	2.0	12
12	Innovative use of Ïƒ and Ï€ electron acceptors in the development of three high throughput 96-microwell spectrophotometric assays for crizotinib. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2021, 259, 119884.	2.0	1
13	Synthesis, cytotoxic evaluation, and molecular docking studies of novel quinazoline derivatives with benzenesulfonamide and anilide tails: Dual inhibitors of EGFR/HER2. Bioorganic Chemistry, 2020, 95, 103461.	2.0	41
14	Stability indicating spectrophotometric methods for quantitative determination of bromazepam and its degradation product. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2020, 238, 118433.	2.0	8
15	Development of innovative artificial neural networks for simultaneous determination of lapatinib and foretinib in human urine by micellar enhanced synchronous spectrofluorimetry. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2020, 238, 118438.	2.0	7
16	In silico and in vitro metabolism of ribociclib: a mass spectrometric approach to bioactivation pathway elucidation and metabolite profiling. RSC Advances, 2020, 10, 22668-22683.	1.7	16
17	Metabolic Stability Assessment of Larotrectinib Using Liquid Chromatography Tandem Mass Spectrometry . Drug Design, Development and Therapy, 2020, Volume 14, 111-119.	2.0	4
18	Experimental and computational evaluation of kolliphor RH 40 as a new fluorescence enhancer in development of a micellar-based spectrofluorimetric method for determination of lapatinib in tablets and urine. PLoS ONE, 2020, 15, e0239918.	1.1	3

#	Article	IF	Citations
19	Orthogonal projection to latent structures and first derivative for manipulation of PLSR and SVR chemometric models' prediction: A case study. PLoS ONE, 2019, 14, e0222197.	1.1	11
20	Development of novel response surface methodology-assisted micellar enhanced synchronous spectrofluorimetric method for determination of vandetanib in tablets, human plasma and urine. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2019, 213, 272-280.	2.0	5
21	Validated liquid chromatography tandem mass spectrometry for simultaneous quantification of foretinib and lapatinib, and application to metabolic stability investigation. RSC Advances, 2019, 9, 19325-19332.	1.7	7
22	Identification of reactive intermediate formation and bioactivation pathways in Abemaciclib metabolism by LCâ€“MS/MS: in vitro metabolic investigation. Royal Society Open Science, 2019, 6, 181714.	1.1	24
23	Reactive intermediates in naquotinib metabolism identified by liquid chromatography-tandem mass spectrometry: phase I metabolic profiling. RSC Advances, 2019, 9, 10211-10225.	1.7	2
24	Belizatinib: Novel reactive intermediates and bioactivation pathways characterized by LCâ€“MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2019, 171, 132-147.	1.4	13
25	Investigation of metabolic stability of the novel ALK inhibitor brigatinib by liquid chromatography tandem mass spectrometry. Clinica Chimica Acta, 2018, 480, 180-185.	0.5	27
26	A reliable and stable method for the determination of foretinib in human plasma by LC-MS/MS: Application to metabolic stability investigation and excretion rate. European Journal of Mass Spectrometry, 2018, 24, 344-351.	0.5	31
27	LC-ESI-MS/MS reveals the formation of reactive intermediates in brigatinib metabolism: elucidation of bioactivation pathways. RSC Advances, 2018, 8, 1182-1190.	1.7	28
28	LC-MS/MS reveals the formation of reactive ortho -quinone and iminium intermediates in saracatinib metabolism: Phase I metabolic profiling. Clinica Chimica Acta, 2018, 482, 84-94.	0.5	25
29	Investigation of the metabolic stability of olmutinib by validated LC-MS/MS: quantification in human plasma. RSC Advances, 2018, 8, 40387-40394.	1.7	28
30	Identification and characterization of in vivo, in vitro and reactive metabolites of vandetanib using LCâ€“ESIâ€“MS/MS. Chemistry Central Journal, 2018, 12, 99.	2.6	33
31	Characterization of in vivo metabolites in rat urine following an oral dose of masitinib by liquid chromatography tandem mass spectrometry. Chemistry Central Journal, 2018, 12, 61.	2.6	4
32	LC-ESI-MS/MS identification and characterization of ponatinib in vivo phase I and phase II metabolites. Clinica Chimica Acta, 2018, 485, 144-151.	0.5	7
33	Five modified classical least squares based models for stability indicating analysis of cyclobenzaprine HCl with its major degradation products: A comparative study. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2018, 204, 598-602.	2.0	4
34	Investigation of metabolic degradation of new ALK inhibitor: Entrectinib by LC-MS/MS. Clinica Chimica Acta, 2018, 485, 298-304.	0.5	38
35	Spectroscopic and molecular docking studies of the binding of the angiotensin II receptor blockers (ARBs) azilsartan, eprosartan and olmesartan to bovine serum albumin. Journal of Luminescence, 2018, 203, 616-628.	1.5	19
36	LCâ€“MS/MS reveals the formation of iminium and quinone methide reactive intermediates in entrectinib metabolism: In vivo and in vitro metabolic investigation. Journal of Pharmaceutical and Biomedical Analysis, 2018, 160, 19-30.	1.4	37

#	Article	IF	Citations
37	Identification and characterization of in vitro phase I and reactive metabolites of masitinib using a LC-MS/MS method: bioactivation pathway elucidation. RSC Advances, 2017, 7, 4479-4491.	1.7	35
38	LC-MS/MS reveals the formation of aldehydes and iminium reactive intermediates in foretinib metabolism: phase I metabolic profiling. RSC Advances, 2017, 7, 36279-36287.	1.7	31
39	Liquid chromatography tandem mass spectrometry method for the quantification of vandetanib in human plasma and rat liver microsomes matrices: metabolic stability investigation. Chemistry Central Journal, 2017, 11, 45.	2.6	28
40	Fluorescence spectroscopic and molecular docking studies of the binding interaction between the new anaplastic lymphoma kinase inhibitor crizotinib and bovine serum albumin. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2017, 171, 174-182.	2.0	65
41	LCâ€“MS/MS method for the quantification of masitinib in RLMs matrix and rat urine: application to metabolic stability and excretion rate. Chemistry Central Journal, 2017, 11, 136.	2.6	30
42	Quantification of total mercury in compact fluorescent lamps in Saudi Arabia using inductively coupled plasma mass spectrometry (ICP-MS). Main Group Chemistry, 2016, 15, 117-124.	0.4	1
43	Rapid validated liquid chromatographic method coupled with Tandem mass spectrometry for quantification of nintedanib in human plasma. Tropical Journal of Pharmaceutical Research, 2016, 15, 2467.	0.2	13
44	A new spectrofluorimetric assay method for vandetanib in tablets, plasma and urine. Tropical Journal of Pharmaceutical Research, 2016, 15, 2219.	0.2	7
45	A novel method to determine new potent angiotensin inhibitor, azilsartan, in human plasma via micelle-enhanced spectrofluorimetry using cremophor RH 40. Tropical Journal of Pharmaceutical Research, 2016, 15, 1003.	0.2	1
46	Highly Sensitive Micellar Enhanced Spectrofluorimetric Method for Determination of Mirtazapine in Tablets and Human Urine: Application to In Vitro Drug Release and Content Uniformity Test. Journal of Chemistry, 2016, 2016, 1-8.	0.9	2
47	Determination of Cefoperazone Sodium in Presence of Related Impurities by Improved Classical Least Squares Chemometric Methods: A Comparative Study. Journal of Chemistry, 2016, 2016, 1-8.	0.9	2
48	Comparative Study of Novel Ratio Spectra and Isoabsorptive Point Based Spectrophotometric Methods: Application on a Binary Mixture of Ascorbic Acid and Rutin. Journal of Analytical Methods in Chemistry, 2016, 2016, 1-12.	0.7	4
49	Enhanced spectrofluorimetric determination of the multitargeted tyrosine kinase inhibitor, crizotinib, in human plasma via micelle-mediated approach. Tropical Journal of Pharmaceutical Research, 2016, 15, 2209.	0.2	7
50	Validated LC-MS/MS Method for the Quantification of Ponatinib in Plasma: Application to Metabolic Stability. PLoS ONE, 2016, 11, e0164967.	1.1	29
51	A highly efficient and sensitive LCâ€MS/MS method for the determination of afatinib in human plasma: application to a metabolic stability study. Biomedical Chromatography, 2016, 30, 1248-1255.	0.8	28
52	Detection and characterization of ponatinib reactive metabolites by liquid chromatography tandem mass spectrometry and elucidation of bioactivation pathways. RSC Advances, 2016, 6, 72575-72585.	1.7	34
53	Full spectrum and selected spectrum based multivariate calibration methods for simultaneous determination of betamethasone dipropionate, clotrimazole and benzyl alcohol: Development, validation and application on commercial dosage form. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2016, 169, 50-57.	2.0	9
54	Simultaneous quantitative analysis of olmesartan, amlodipine and hydrochlorothiazide in their combined dosage form utilizing classical and alternating least squares based chemometric methods. Acta Pharmaceutica, 2016, 66, 83-95.	0.9	9

#	Article	IF	Citations
55	Advanced stability indicating chemometric methods for quantitation of amlodipine and atorvastatin in their quinary mixture with acidic degradation products. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2016, 154, 58-66.	2.0	12
56	Micellar Enhanced Spectrofluorimetric Method for the Determination of Ponatinib in Human Plasma and Urine via Cremophor RH 40 as Sensing Agent. International Journal of Analytical Chemistry, 2015, 2015, 1-9.	0.4	10
57	Micellar enhanced synchronous spectrofluorimetric method for determination of dasatinib in tablets, human plasma and urine: application to in vitro drug release and content uniformity test. RSC Advances, 2015, 5, 54471-54480.	1.7	16
58	A new method to determine the new C-Met inhibitor â€œCabozantinibâ€•in dosage form and human plasma via micelle-enhanced spectrofluorimetry. RSC Advances, 2015, 5, 40484-40490.	1.7	11
59	Design, Synthesis, Characterization of Novel Ruthenium(II) Catalysts: Highly Efficient and Selective Hydrogenation of Cinnamaldehyde to (E)-3-Phenylprop-2-en-1-ol. Molecules, 2014, 19, 5965-5980.	1.7	3
60	A Stability-Indicating HPLC-DAD Method for Determination of Stiripentol: Development, Validation, Kinetics, Structure Elucidation and Application to Commercial Dosage Form. Journal of Analytical Methods in Chemistry, 2014, 2014, 1-10.	0.7	9
61	DNA Binding Test, X-Ray Crystal Structure, Spectral Studies, TG-DTA, and Electrochemistry of [CoX2(dmdphphen)] (Dmdphphen Is 2,9-Dimethyl-4,7-diphenyl-1,10-phenanthroline, X = Cl, and NCS) Complexes. Bioinorganic Chemistry and Applications, 2014, 2014, 1-7.	1.8	2
62	Different approaches in Partial Least Squares and Artificial Neural Network models applied for the analysis of a ternary mixture of Amlodipine, Valsartan and Hydrochlorothiazide. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2014, 122, 744-750.	2.0	23
63	Crystal structure of (2E)-2-[3-(1H-imidazol-1-yl)-1-phenylpropylidene]-N-(4-methylphenyl)hydrazinecarboxamide, C20H21N5O. Zeitschrift Fur Kristallographie - New Crystal Structures, 2014, 229, 311-312.	0.1	1
64	Improved partial least squares models for stabilityâ€•indicating analysis of mebeverine and sulpiride mixtures in pharmaceutical preparation: A comparative study. Drug Testing and Analysis, 2013, 5, 325-333.	1.6	9
65	Application of smart spectrophotometric methods and artificial neural network for the simultaneous quantitation of olmesartan medoxamil, amlodipine besylate and hydrochlorothiazide in their combined pharmaceutical dosage form. Chemistry Central Journal, 2013, 7, 22.	2.6	16
66	Three different methods for determination of binary mixture of Amlodipine and Atorvastatin using dual wavelength spectrophotometry. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2013, 104, 70-76.	2.0	49
67	Comparative study between derivative spectrophotometry and multivariate calibration as analytical tools applied for the simultaneous quantitation of Amlodipine, Valsartan and Hydrochlorothiazide. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2013, 113, 215-223.	2.0	35
68	Multivariate Versus Classical Univariate Calibration Methods for Spectrofluorimetric Data: Application to Simultaneous Determination of Olmesartan Medoxamil and Amlodipine Besylate in their Combined Dosage Form. Journal of Fluorescence, 2013, 23, 79-91.	1.3	19
69	Comparative ANNs with Different Input Layers and GA-PLS Study for Simultaneous Spectrofluorimetric Determination of Melatonin and Pyridoxine HCl in the Presence of Melatoninâ€™s Main Impurity. Molecules, 2013, 18, 974-996.	1.7	11
70	New spectrofluorimetric methods for determination of melatonin in the presence of N-{2-[1-({3-[2-(acetylamino)ethyl]-5-methoxy-1H-indol-2-yl}methyl)-5-methoxy-1H-indol-3-yl]-ethyl}acetamide: a contaminant in commercial melatonin preparations. Chemistry Central Journal, 2012, 6, 36.	2.6	5
71	Support vector regression and artificial neural network models for stability indicating analysis of mebeverine hydrochloride and sulpiride mixtures in pharmaceutical preparation: A comparative study. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2012, 86, 515-526.	2.0	25
72	Three different spectrophotometric methods manipulating ratio spectra for determination of binary mixture of Amlodipine and Atorvastatin. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2011, 83, 140-148.	2.0	87

#	Article	IF	Citations
73	Stabilityâ€indicating chemometric methods for the determination of tazarotene. Drug Testing and Analysis, 2010, 2, 357-361.	1.6	8